Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Blastomycosis Treatment Market Set To Climb From $0.79 Billion In 2026 To $1.07 Billion By 2030
The blastomycosis treatment market has experienced robust growth in recent years. It is projected to expand from $0.73 billion in 2025 to $0.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.6%. This historical increase can be attributed to enhanced awareness of systemic fungal infections, the availability of antifungal drug therapies, the expansion of diagnostic laboratory services, greater clinical recognition of blastomycosis cases, and the development of infectious disease treatment programs.
The blastomycosis treatment market is projected to experience substantial expansion over the upcoming years. By 2030, this market is forecast to reach a valuation of $1.07 billion, demonstrating a compound annual growth rate (CAGR) of 7.9%. This anticipated growth during the forecast period is primarily driven by a heightened emphasis on timely and precise diagnosis, the ongoing advancement of superior antifungal formulations, the proliferation of specialized centers for infectious disease care, an expanding adoption of personalized treatment strategies, and increased financial commitment to fungal disease research. Key trends expected throughout this period encompass the wider implementation of sophisticated diagnostic protocols, an increasing application of targeted antifungal treatments, the broadening of therapeutic drug monitoring practices, a strengthened focus on the early identification of diseases, and improved integration of clinical decision support tools.
Get A Free Sample Report With In-Depth Market Insights:
Blastomycosis Treatment Market Growth Factors Behind Sustained Expansion
The escalating occurrence of fungal diseases is anticipated to boost the expansion of the blastomycosis treatment market in the coming years. Fungal diseases are infections caused by harmful fungi capable of entering the body via inhalation, direct contact, or environmental exposure. This uptick in fungal disease cases largely stems from climate-related environmental shifts, as increased rainfall and flooding create damp, organic soil conditions conducive to the proliferation of fungal spores and subsequent human contact. The rising prevalence of fungal infections necessitates effective treatment options, given that timely diagnosis and appropriate antifungal therapy are crucial for averting serious complications and lowering mortality rates. For instance, in May 2025, according to the UK Health Security Agency, a UK-based government agency, bloodstream infections attributed to yeast increased by 4% in 2024 compared with 2023, rising from 2,170 to 2,247 reported cases. Consequently, the increasing incidence of fungal diseases is fueling the growth of the blastomycosis treatment market. The expanding population of immunocompromised individuals is projected to stimulate the growth of the blastomycosis treatment market in the foreseeable future. This demographic comprises people with weakened immune systems due to underlying health issues, genetic predispositions, or medical interventions such as chemotherapy, immunosuppressive medications, or organ transplants. The rise in the immunocompromised population is attributable to enhanced survival rates among those with chronic conditions, coupled with the increased application of immunosuppressive and immunomodulating therapies for autoimmune and inflammatory disorders. Blastomycosis treatment offers vital support to immunocompromised patients by delivering effective antifungal therapy that manages severe and widespread infections, diminishes fungal load, and prevents life-threatening health issues in individuals with compromised immunity. For instance, in September 2024, according to Infection & Chemotherapy (IC), a South Korea–based journal, as of December 2023, South Korea had reported a cumulative total of 19,001 individuals diagnosed with HIV, of whom 1,219 (6.4%) were women. In 2022 alone, 1,066 new HIV cases were identified, including 82 women (7.7%), comprising 35 Korean nationals and 47 foreign nationals. During the same year, the total number of Korean nationals living with HIV in the country reached 15,880, with women accounting for 998 cases. Therefore, the increasing immunocompromised population is driving the growth of the blastomycosis treatment market.
Blastomycosis Treatment Market Segment Trends And Revenue Contributors
The blastomycosis treatment market covered in this report is segmented –
1) By Treatment Type: Antifungal Drugs; Surgical Intervention
2) By Anatomy: Lung; Bones; Central Nervous System; Other Anatomy
3) By Dosage: Tablet; Injection; Capsule; Other Dosage forms
4) By Route Of Administration: Intravenous; Oral; Other Route Of Administrations
5) By End-User: Hospitals; Outpatient Clinics; Diagnostic Laboratories
Subsegments:
1) By Antifungal Drugs: Azole Antifungal Agents; Polyene Antifungal Agents; Echinocandin Antifungal Agents; Oral Antifungal Formulations; Intravenous Antifungal Formulations
2) By Surgical Intervention: Lesion Debridement Procedures; Abscess Drainage Procedures; Lung Resection Procedures; Soft Tissue Excision Procedures
Blastomycosis Treatment Market Industry Trends Fueling Future Revenue Growth
Leading companies in the blastomycosis treatment market are focused on creating advanced solutions, particularly in antifungal drug development. This initiative aims to achieve better treatment efficacy, improved safety profiles, and a stronger position in addressing the unmet needs for severe systemic fungal infections. Antifungal drug development entails devising new antifungal therapies intended to enhance existing treatments by boosting effectiveness, lowering toxicity, overcoming drug resistance, and offering superior dosing, formulation, or delivery methods. For example, in June 2024, Elion Therapeutics, a US-based biotechnology company, announced SF001, a next-generation polyene antifungal and a novel analog of amphotericin B. Amphotericin B is a long-established primary treatment for severe systemic fungal infections, including blastomycosis. While the press release specifically mentioned invasive fungal infections such as aspergillosis, SF001’s mechanism of action as an amphotericin B derivative, designed to maintain broad-spectrum antifungal activity while reducing toxicity, also makes it relevant for blastomycosis treatment. This means that since amphotericin B is effective against Blastomyces dermatitidis, a drug built upon its structure and function, like SF001, has a logical connection to blastomycosis therapy.
Blastomycosis Treatment Market Leading Companies And Competitive Benchmarking
Major companies operating in the blastomycosis treatment market are Johnson & Johnson, Pfizer Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Astellas Pharma Inc., bioMérieux SA, Cipla Ltd., Lupin Limited, SCYNEXIS Inc., and F2G Ltd.
View The Full Blastomycosis Treatment Market Report:
Blastomycosis Treatment Market Largest Region By Revenue And Market Share
North America was the largest region in the blastomycosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blastomycosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model